You are here: Industry Insights > BMS

News List

Draper, BMS Sign Toxicity Testing Pact contractpharma
July 01, 2019
Companies to develop unique liver tissue model for screening toxicity of drugs.
BMS to divest Otezla for approval of $74bn merger with Celgene pharmaceutical-technology
June 26, 2019
Bristol-Myers Squibb (BMS) has offered to divest prescription medicine Otezla in order to receive approval for its $74bn merger with Celgene from the US Federal Trade Commission (FTC).
BMS’ Opdivo fails to reach primary endpoint in HCC pharmaceutical-technology
June 26, 2019
Bristol Myers-Squibb (BMS) has announced that its blockbuster cancer drug Opdivo (nivolumab) has failed to reach its primary endpoint in the Phase III CheckMate-459 trial.
Catalent to Purchase BMS Mfg. Facility in Anagni, Italy contractpharma
June 20, 2019
Catalent will continue to manufacture BMS products while offering access to sterile biologics fill/finish and oral solids manufacturing and packaging platforms.
BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland pharmaceutical-technology
June 13, 2019
Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients ...
Promising early results for BMS’ investigational HCC study pharmatimes
June 05, 2019
Bristol-Myers Squibb (BMS) has announced the first results from its investigational Opdivo (nivolumab) plus Yervoy (ipilimumab) cohorts of the Phase I/II CheckMate -040 study at the American Society of Clinical Oncology (ASCO) meeting 2019.
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme pharmafile
May 16, 2019
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating its efficacy in the treatment of ...
BMS’ Opdivo fails in Phase III glioblastoma trial pharmaceutical-technology
May 13, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial.
NICE asks BMS for more data before approving cancer drug europeanpharmaceuticalreview
May 08, 2019
NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma…
Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut fiercepharma
April 23, 2019
Bristol-Myers Squibb investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble just arrived two months early.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page